• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Sutro Biopharma Inc.

    4/22/26 4:15:13 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $STRO alert in real time by email
    DEFA14A
    0001382101falseDEFA14A00013821012025-01-012025-12-31

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (AMENDMENT NO. )

    Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐

    Check the appropriate box:

    ☐ Preliminary Proxy Statement

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐ Definitive Proxy Statement

    ☒ Definitive Additional Materials

    ☐ Soliciting Material Pursuant to §240.14a-12

    SUTRO BIOPHARMA, INC.

    (Name of Registrant as Specified In Its Charter)

    N/A

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check the appropriate box):

    ☒ No fee required.

    ☐ Fee paid previously with preliminary materials.

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     


     

     

    img171419051_0.jpg

    SUTR·J BIOPHARMA SUTRO BIOPHARMA, INC. 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO, CALIFORNIA 94080 You invested in SUTRO BIOPHARMA, INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on June 05, 2026.Get informed before you vote View the Notice & Proxy Statement, Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 22, 2026. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Smartphone users Point your camera here and vote without entering a I number Virtually at: Vote Virtually at the Meeting*June 05, 2026 8:00 AM PDT www.virtualshareholdermeeting.com/STR02026*Please check the meeting materials for any special requirements for meeting attendance.

     


     

     

    img171419051_1.jpg

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.Voting Items 1.Election of Class II Directors Nominees:01)Jane Chung, RPh 02)Connie Matsui 03)James Panek Board Recommends 2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026.3.To approve, on a non-binding, advisory basis, the compensation of our named executive officers.NOTE: Such other business as may properly come before the meeting or any adjournment thereof.0For OFor Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".

     


    Get the next $STRO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STRO

    DatePrice TargetRatingAnalyst
    4/7/2026$38.00Outperform
    Leerink Partners
    3/24/2026$27.00Equal Weight → Overweight
    Wells Fargo
    3/24/2026$28.00Neutral → Buy
    H.C. Wainwright
    1/20/2026$23.00Mkt Perform → Mkt Outperform
    Citizens JMP
    6/16/2025$2.00Neutral → Overweight
    Piper Sandler
    3/17/2025Buy → Neutral
    H.C. Wainwright
    3/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    3/14/2025$8.00 → $2.00Outperform → Neutral
    Wedbush
    More analyst ratings

    $STRO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF SCIENTIFIC OFFICER Gerber Hans-Peter bought $13,607 worth of shares (17,000 units at $0.80), increasing direct ownership by 31% to 71,832 units (SEC Form 4)

    4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)

    10/16/25 8:19:45 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CFO Chow Gregory K. bought $15,998 worth of shares (19,750 units at $0.81) (SEC Form 4)

    4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)

    10/16/25 8:18:45 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Chung Jane bought $10,011 worth of shares (12,500 units at $0.80), increasing direct ownership by 11% to 122,850 units (SEC Form 4)

    4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)

    10/16/25 8:17:03 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $STRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Sutro Biopharma with a new price target

    Leerink Partners initiated coverage of Sutro Biopharma with a rating of Outperform and set a new price target of $38.00

    4/7/26 8:50:07 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sutro Biopharma upgraded by Wells Fargo with a new price target

    Wells Fargo upgraded Sutro Biopharma from Equal Weight to Overweight and set a new price target of $27.00

    3/24/26 8:28:11 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sutro Biopharma upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Sutro Biopharma from Neutral to Buy and set a new price target of $28.00

    3/24/26 8:28:11 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $STRO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026

    STRO-004 demonstrates robust and consistent antitumor activity across multiple TF-expressing solid tumor PDX models, with improved efficacy versus benchmark ADCs STRO-006 and STRO-227 show meaningful, dose-dependent antitumor activity across solid tumor models Presentation of TROP2-targeted immunostimulatory ADC program partnered with Astellas highlights the potential of Sutro's platform for developing dual-payload ADCs SOUTH SAN FRANCISCO, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced promising preclinical

    4/19/26 7:45:00 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

    – Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned dual-payload program targeting PTK7, STRO-227, accelerating IND submission to 2026 – – Astellas-partnered iADC dual-payload program enters the clinic; patient dosing underway – – Cash, cash equivalents and marketable securities as of December 31, 2025 of $141.4 million, excluding proceeds from the recent capital raise of approximately $110 million which extended cash runway into at least the second quarter of 2028 – SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma,

    3/23/26 4:05:00 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sutro Biopharma to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in several upcoming investor conferences. Conference Details: TD Cowen 46th Annual Health Care Conference Date: March 2-4, 2026Location: Boston, MA Leerink Partners Global Healthcare ConferenceDate: March 8-11, 2026 Location: Miami, FL The Citizens Life Sciences Conference Date: March 10-11, 2026Location: Miami, FL Barclays 28th Annual Global Healthcare ConferenceDate: March 10-12, 2026Location: Miami, FL We

    2/25/26 8:30:00 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $STRO
    SEC Filings

    View All

    SEC Form DEFA14A filed by Sutro Biopharma Inc.

    DEFA14A - SUTRO BIOPHARMA, INC. (0001382101) (Filer)

    4/22/26 4:15:13 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEF 14A filed by Sutro Biopharma Inc.

    DEF 14A - SUTRO BIOPHARMA, INC. (0001382101) (Filer)

    4/22/26 4:05:18 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Sutro Biopharma Inc.

    SCHEDULE 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)

    4/21/26 5:49:09 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $STRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Admin. Ofcr. & GC Pauling David converted options into 675 shares and covered exercise/tax liability with 277 shares, increasing direct ownership by 4% to 9,748 units (SEC Form 4)

    4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)

    3/6/26 4:25:03 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Chung Jane converted options into 788 shares and covered exercise/tax liability with 282 shares, increasing direct ownership by 2% to 21,285 units (SEC Form 4)

    4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)

    3/6/26 4:21:10 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Admin. Ofcr. & GC Pauling David converted options into 3,698 shares and covered exercise/tax liability with 1,521 shares, increasing direct ownership by 30% to 9,350 units (SEC Form 4)

    4 - SUTRO BIOPHARMA, INC. (0001382101) (Issuer)

    3/3/26 6:59:49 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $STRO
    Financials

    Live finance-specific insights

    View All

    Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

    – Sutro announced a strategic portfolio review resulting in prioritization of wholly-owned next-generation ADC programs; Key management changes announced as part of transition – – Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million, with cash runway expected into at least Q4 2026, excluding anticipated milestones from existing collaborations – – Conference call today at 2:00 p.m. PT / 5:00 p.m. ET – SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial resu

    3/13/25 4:07:00 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

    – Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs for wholly-owned programs expected in the next 3 years, beginning with novel Tissue Factor ADC, STRO-004, planned for 2H 2025 – – Jane Chung, President and COO, to succeed Bill Newell as CEO and Board Director – – Cash, cash equivalents and marketable securities as of December 31, 2024 of $316.9 million, with cash runway expected into at least Q4 2026, excluding anticipated milestones from existing collaborations – – Conference call today at 2:00 p.m. PT/ 5:00 p.m. ET – SOUTH SAN FRANCISCO, Calif

    3/13/25 4:05:00 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer

    - Conference call and webcast to be held on Monday, January 9, 2023 at 1:30 pm PT, or 4:30 pm ET - SOUTH SAN FRANCISCO, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced it will host a conference call and webcast to present data from its Phase 1 dose-expansion trial and a registrational path forward for STRO-002, an ADC being developed for the treatment of advanced ovarian cancer. In addition to members of the Sutro management team, the call will feature Dr. R. Wendel Naumann, Investigator in the STRO-002-GM1 stud

    12/21/22 8:00:00 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $STRO
    Leadership Updates

    Live Leadership Updates

    View All

    Sutro Biopharma Appoints Greg Chow as Chief Financial Officer

    SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Greg Chow as Chief Financial Officer (CFO), effective June 2, 2025. Mr. Chow brings over 25 years of executive leadership experience across corporate finance, capital markets, investment banking, financial accounting, and drug development operations. "We are delighted to welcome Greg to Sutro's executive leadership team," said Jane Chung, Chief Executive Officer of Sutro. "Greg brings a strong track record of driving financial discipline, o

    6/2/25 8:00:00 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

    - Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the first half of 2025 - - REFRαME-O1 Part 2 (randomized portion) of the Phase 3 trial of luvelta for treatment of platinum-resistant ovarian cancer (PROC) is underway - - REFRαME-P1, a registration-enabling trial of luvelta for pediatric patients with CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) AML, is expected to be initiated in the second half of 2024 - - A Phase 2 trial of luvelta for the treatment of NSCLC is expected to initiate in the second half of 2024, with initial data expect

    8/13/24 4:30:00 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

    SOUTH SAN FRANCISCO, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Barbara Leyman, Ph.D., as Chief Business Development Officer, effective July 8, 2024. Dr. Leyman brings 20 years of life science industry business development, investing, and corporate strategy experience to Sutro. "We are thrilled to welcome Dr. Leyman at a pivotal time for Sutro, as we advance luvelta in two registration-directed trials in both ovarian cancer and a rare pediatric cancer and continue to leverage our proprieta

    7/9/24 8:00:00 AM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $STRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sutro Biopharma Inc.

    SC 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)

    11/14/24 7:54:45 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sutro Biopharma Inc.

    SC 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)

    11/14/24 4:30:53 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sutro Biopharma Inc.

    SC 13G/A - SUTRO BIOPHARMA, INC. (0001382101) (Subject)

    11/13/24 4:30:25 PM ET
    $STRO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care